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ABSTRACT (Maximum 200 Words)
Prostate cancer is now the most common cancer among men in the United States. Angiogenesis is required for prostate tumor survival, growth, and metastasis. We proposed to design novel Hunter-Killer Peptides (HKPs), each representing a chimeric peptide of an angiogenesis-targeting peptide and a mitochondrial membrane-disrupting peptide.
While non-toxic in the circulation, the HKPs will be preferentially toxic to mitochondria once internalized into angiogenic cells, via the targeting domain. As we reported in Ellerby et al., Nature Medicine, 5, 1032-1038, 1999, our prototypes contain only 21 and 26 amino acid residues, are selectively toxic to angiogenic endothelial cells and show strong anti-cancer activity in mice (breast carcinoma xenografts) .
In the work described here, we evaluated the HKPs for efficacy and toxicity in a xenograft model of human prostate carcinoma, and in the TRAMP (transgenic adenocarcinoma mouse prostate) model for prostate cancer. The central theme of this research is to develop and appraise this new chemotherapy with the goal of producing both a safer, and more effective, treatment of advanced prostate cancer.
Introduction
The subject of our research is prostate cancer. The purpose of this research is the development of a more effective and less toxic treatment for prostate cancer. The currently used chemo-therapeutic agents are drugs with the narrowest therapeutic index in all of medicine. Therefore, effective doses of a wide variety of anti-cancer agents are restricted by their non-selective, highly toxic effect on normal tissues. In response to this, we designed short peptides composed of two functional domains, one a tumor blood vessel 'homing' sequence and the other a programmed cell deathinducing sequence, and synthesized them by basic peptide chemistry. The 'homing' domain was designed to guide the peptide to targeted cells and permit its internalization. The pro-apoptotic domain was designed to be non-toxic outside all cells, but toxic when internalized into just the targeted cells by the disruption of mitochondrial membranes.
Thus our approach was to create non-toxic anticancer peptides, which we named HunterKiller Peptides (HKP), designed to only destroy tumor blood vessels while leaving normal blood vessels unharmed. As presented in Ellerby et al., 1999 , we succeeded in the development of HKPs, demonstrating that although our 2 prototypes contained only 21 and 26 amino acid residues, they were selectively toxic to angiogenic endothelial cells and had strong anti-cancer activity in mice. Furthermore, in Arap et al., 2002 , we showed that HKPs delayed the development of the cancers in prostate cancer-prone transgenic mice (TRAMP mice). Moreover we elaborate on our previous report that HKPs can be given IP (intraperitoneal) in addition to IV (intravenous; tail vein injection in mice), opening up the possibility to administer our peptides more than once a week. We found that IP injection of 2 of our prototypes was more effective at reduces tumor volumes than IV. A manuscript on this work is now in preparation. We also discuss problems and solutions to those problems encountered this year with our CNGRC-based peptides, involving peptide quality, and receptor expression. We conclude this part of the report with a discussion of a study that we have just begun to treat TRAMP mice that spontaneously get prostate cancer, with a dual therapy designed to attack the prostate tumors blood vessels and the prostate cells as well. These studies will be completed at the end of August, 2004.
We also review and elaborate on our previous report concerning a new anti-cancer therapy that complements our work on targeted antiangiogenic peptides. We have discovered that certain membrane-disrupting/pore-forming peptides can be quite effective as direct anti-neoplastic agents (directly killing cancer cells). Specifically, we review here, as described in our recent published paper (Ellerby et al., 2003) , that a 69 amino acid peptide, Small Globular Protein (SGP) can reduce tumor volume (eliminating some tumors), and increase survival, in a xenograft model of human prostate carcinoma. We conclude this report with a discussion of a study that we have just begun to treat TRAMP mice that spontaneously get prostate cancer, with a dual therapy designed to attack both the prostate tumors blood vessels and the prostate cells.
Body
Our work to date in designing, synthesizing, and testing Hunter-Killer Peptides (HKPs), and Small Globular Protein (SGP), is described in the accompanying reprints by Ellerby et al., 1999, and Arap et al., 2002 , and in our newly published paper Ellerby et al., 2003 , in the appendix. In the following, we re-state the approved Statement of Work, and then summarize how we have met our goals so far. Ellerby et al. 2003 , for a discussion of these results). Furthermore, we also reported in Arap et al., 2002 , that HKPs delayed the development of the cancers in prostate cancer-prone transgenic mice (TRAMP mice). Thus we are already ahead of schedule on this task, having already demonstrated the efficacy of HKPs in this transgenic mouse model. We have now begun work on the process of optimizing the doses of HKPs in the TRAMP model, and have proceeded to formulate a study in TRAMP mice involving the dual use of HKP's to simultaneously target the angiogenic blood vessels of prostate tumors and the normal prostate cells. This work in progress and will be completed in the end of August. Furthermore, based on these initial results, we plan later this year to also include in some combination with HKP therapy, targeted nanoparticles containing SGP. Task 2. We are currently designing new HKPs, so this Task is in progress, and will continue throughout the life of these studies. In particular, a new killer sequence has been developed, ALLLAIRRRKKK, based on an antibacterial peptide produced in moths. Initial tests of the efficacy of this peptide in our in vitro tissue culture models (see Ellerby et al. 1999) , demonstrate that this killing sequence is 1,000-5,000 times more effective than our original killing peptide KLAKLAKKLAKLAK, as measured by the therapeutic index calculated as the ratio of the concentration required to kill normal untargeted cells divided by the concentration required to kill targeted cells. In addition, we have discovered that SGP (see introduction) can be used as a complementary therapy to HKPs. While HKPs target and destroy tumor vasculature, SGP directly kills tumor cells when injected intratumorally. This data is summarized below, and in our recent paper, Ellerby et al., 2003. Task 3. We are currently testing new HKPs, so this Task is always in progress, and as described above, we have been focusing on HKP's with a new ALLLAIRRRKKK killing domain, for which initial tissue culture studies suggest that this new HKP will be over 1,000 times more effective. Task 4 and Task 5. These tasks are in progress. There was some delay this past year in beginning these studies because we had problems of peptide purity (the peptides are manufactured commercially), and were informed by a colleague that the CNGRC targeting moiety might not be the most optimal targeting peptide to employ, due to variances in receptor expression. This peptide had been selected over more complex targeting peptides such as our ACDCRGDCFC (bicyclic with 2 disulfide bonds) targeting peptide, due to issues involving the cost and complexity of synthesis of the RGD-based targeting peptide. We were fortunate to discover the above before embarking on our complex and expensive TRAMP studies. We will begin our TRAMP study this month using the RGD-based targeting sequence, to target the tumor blood vessels, and the SMSbased targeting sequence (see Arap et al., 2002) . In addition, we have been forced by the quality issues to switch to another custom peptide synthesis company. We have also discovered that CNGRC is more effective at targeting in a particular chemical form and have a paper in progress on the receptor based mechanism of this discovery.
Key Research Accomplishments
" We successfully designed and tested a Hunter-Killer Peptide, SMSIARL-GG-D(KLAKLAK) 2 , in the TRAMP Mouse Model of Prostate Cancer. This work is described in Arap et al., 2002 .
" We successfully published a paper on our design and evaluation of SGP. As described above, we successfully tested the anti-tumor effects of SGP in human prostate carcinoma xenografts in nude mice. The data show that SGP can reduce tumor volume and extend survival. This data is discussed in detail in Ellerby et al., 2003 , which is attached.
Annual Report DAMD17-01- We worked out issues involving peptide quality (commercial synthesis), and made the decision to switch to a different RGD-based targeting peptide. We discovered this year after a 3 month study that we were having a problem with the peptide company we dealt with, involving issues about timely delivery and quality of peptide. We also decided to switch to our RGD-based targeting peptide, in part because some of our in vitro tests were inconsistent from peptide batch to peptide batch. This situation was clouded by real concern over quality, but even so, colleagues reported to us that they were just getting a better result with our RGD-based targeting peptide. Thus, in the studies we are about to begin on TRAMP mice, we will be using the RGD-based targeting peptide for HKP's designed to target angiogenic vasculature.
Reportable Outcomes
Papers, manuscripts, abstracts, presentations Patents and licenses applied for and/or issued We will be applying for a patent on the use of SGP. This has been reported in the Inventions Report to the DAMD.
Degrees obtained that are supported by this award None.
Development of cell lines, tissue or serum repositories None.
Informatics such as databases and animal models, etc See ref. Funding applied for based on work supported by this award None at this time.
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Annual Report DAMD17-01-1-0029 Employment or research opportunities applied for and/or received on experiences/training supported by this award None at this time.
Conclusions
We have designed short peptides, Hunter Killer Peptides (HKP), composed of two functional domains, one a tumor blood vessel 'homing' motif and the other a programmed cell death-inducing sequence, and synthesized them by simple chemistry. The 'homing' domain was designed to guide the peptide to targeted cells and allow internalization. The pro-apoptotic domain was designed to be non-toxic outside cells, but toxic when internalized into targeted cells by the disruption of mitochondrial membranes. We demonstrated in Ellerby et al. 1999 , that HKPs show strong anti-cancer activity in mice (xenografts of human breast carcinomas and melanomas). We also reported here and in Arap et al., 2002 , that HKPs delayed the development of the cancers in prostate cancer-prone transgenic mice (TRAMP mice). The publication of this paper was a milestone for us, and meant that were ahead of schedule with our proposed research (this research was not planned until 2003). Finally, we now have demonstrated the feasibility of using membranedisrupting/pore-forming peptides/proteins as anti-neoplastic agents by evaluating the efficacy of Small Globular Protein (SGP). This work is being published this month, Ellerby et al., 2003 . We now proceed this year to our TRAMP studies, involving the use of HKPs targeted to tumor blood vessels, and HKPs targeted to normal prostate cells. Work will then begin on the consideration of an SGP-targeted therapy, probably involving nanoparticle technology, designed to encase SGP so that it can be injected directly into the blood stream, targeted by a surface coating of targeting peptide. The implications of our work are that it is now possible for humans to engineer targeted and untargeted artificial peptides and proteins to be used systemically and locally as effective anticancer agents.
We have designed short peptides composed of two functional domains, one a tumor blood vessel 'homing' motif and the other a programmed cell death-inducing sequence, and synthesized them by simple peptide chemistry. The 'homing' domain was designed to guide the peptide to targeted cells and allow its internalization. The pro-apoptotic domain was designed to be nontoxic outside cells, but toxic when internalized into targeted cells by the disruption of mitochondrial membranes. Although our prototypes contain only 21 and 26 residues, they were selectively toxic to angiogenic endothelial cells and showed anti-cancer activity in mice. This approach may yield new therapeutic agents.
Tumor cell survival, growth and metastasis require persistent the common ancestry of bacteria and mitochondria'" '. In connew blood vessel growth" (angiogenesis). Consequently, a trast, eukaryotic plasma membranes (outer leaflet) generally strategy has emerged to treat cancer by inhibiting angiogenesis'. have low membrane potentials, and are almost exclusively comPeptides have been described that selectively target angiogenic posed of zwitterionic phospholipids'" 1"'. Many antibacterial endothelial cells' '. Conjugates made from these peptides and peptides, therefore, preferentially disrupt prokaryotic memthe anti-cancer drug doxorubicin induce tumor regression in branes and eukaryotic mitochondrial membranes rather than mice with a better efficacy and a lower toxicity than doxoru-eukaryotic plasma membranes. bicin alone'. There is also a functional class of cell death-inducIf such nontoxic peptides were coupled to tumor targeting ing receptors, or 'dependence receptors', which have embedded peptides that allow receptor-mediated internalization, the pro-apoptotic amino-acid sequences'''. These peptide domains chimeric peptide would have the means to enter the cytosol of are required for apoptosis induction by these receptors. The targeted cells, where it would be toxic by inducing mitochonpeptide fragments are thought to be released into the cytosol as drial-dependent apoptosis"'". Thus, we designed targeted procleavage products of caspase proteolysis, where they induce or apoptotic peptides composed of two functional domains. The potentiate apoptosis through unknown mechanisms "'. targeting domain was designed to guide the 'homing' proHowever, such peptides, and structurally similar pro-apoptotic apoptotic peptides to targeted cells and allow their internalizaantibiotic peptides, although they remain relatively non-toxic tion ,, 22 . The pro-apoptotic domain was designed to be outside of eukaryotic cells, induce mitochondrial swelling and non-toxic outside of cells, but toxic when internalized into tarmitochondria dependent cell-free apoptosis'' 1.
geted cells by the disruption of mitochondrial membranes. There are more than 100 naturally occurring antibiotic peptides, and their de novo design has received mtuch attention"' ". Design of the pro-apoptotic peptide Many of these peptides are linear, cationic and ca-helix-forming. A computer-generated model and the sequence of one of our Some are also amphipathic, with hydrophobic residues distrib-prototypes are shown in Fig. 1 . For the targeting domain, we uted on one side of the helical axis and cationic residues on the used either the cyclic (disulfide bond between cysteines) other". Because their cationic amino acids are attracted to the CNGRC peptide (Fig. 1) or the double-cyclic ACDCRGI)CFC head groups of anionic phospholipids, these peptides preferen-peptide (called RGD-4C), both of which have 'tumor-homing' tially disrupt negatively charged membranes. Once electrostatiproperties"s' and for which there is evidence of internalizacally bound, their amphipathic helices distort the lipid matrix tion"'2. We synthesized this domain from all-L amino acids (with or without pore formation), resulting in the loss of mem-because of the presumed chiral nature of the receptor interacbrane barrier function' ". Both prokaryotic cytoplasmic mem-tion. For the pro-apoptotic domain, we selected the synthetic branes and eukarvotic mitochondrial membranes (both the 14-amino-acid peptide KLAKLAKKLAKLAK (Fig. 1) , called inner and the outer) maintain large transmembrane potentials, (KLAKLAK)2, because it killed bacteria at concentrations 1% of and have a high content of anionic phospholipids, reflecting those required to kill eukaryotic cells". We used the all-D enan-by electron microscopy. The peptide ,(KI.AKLAK), induced abnormal mitochondrial morphology, whereas the control pepHon tide DILSLARI.ATARILAI did not (Fig. 2c) .
Dmainl• Targeted pro-apoptotic peptides induce apoptosis
We evaluated the efficacy and specificity of CNGRC-GG-,(KLAKLAK), in KS1767 cells, derived from Kaposi sarcoma•"' ( Fig. 3a-d) , and MI)A-MB-435 human breast carcinoma cells"' l (Table 1) . We used KS1767 cells because they bind the CNGRC targeting peptide just as endothelial cells do. This may relate to SN --KLAKLAKKLAKLAK the endothelial origin of the KSI1767 cells 2 . We used MDA-MB-435 cells as negative control cells because they do not bind the CNGRC targeting peptide'. Although CNGRC-GG-,(KIAKIAK)2 was considerably toxic to KS16I17 cells, an equimolar mixture of Fig. I Computer-generated model and amino-acid sequence of CNGRC-GG(KLAKLAK),. This peptide is composed of a 'homing' domain (blue) and uncoupled CNGRC and ,(KLAKLAK) , (negative control), or a membrane-disrupting (pro-apoptotic) domain (red hydrophilic and green ,(KLAKLAK)2 alone, was much less toxic, indicative of a targethydrophobic residues), joined by a coupling domain (yellow).
ing effect (Table I ). In contrast, CNGRC-GG-,,(KLAKLAK), was not very toxic to MDA-MB-435 cells, which do not bind the CNGRC peptide ( Table 1 ). The other targeted peptide (RGD-4C)-tiomer )(KLAKLAK), to avoid degradation by proteases"',. This GG-I(KLAKLAK) 2 , showed toxic effects similar to those of strategy was possible because such peptides disrupt membranes CNGRC-GG-,(KLAKI,AK) 2 on KS1617 cells, whereas an equimoby chiral-independent mechanisms 2 ' 2 '. We coupled the targetlar mixture of uncoupled RGD-4C and ,(KLAKLAK) 2 , used as a ing (CNGRC or RGD-4C) and pro-apoptotic I,(KLAKI,AK) 2 do-negative control, was not very toxic (Table 1 ; Fig. 3c -dI). mains with a glycinylglycine bridge ( Fig. 1 ) to impart peptide Although evidence for internalization of CNGRC and RGI)-flexibility and minimize potential steric interactions that 4C into the cytosol of cells has been published',""" 2 , we directly would prevent binding and/or membrane disruption. demonstrated internalization using biotin-labeled peptides. CNGRC-biotin, but not untargeted CARAC-biotin, was inter-D(KLAKLAK)2 disrupts mitochondrial membranes nalized into the cytosol of cells (Fig. 3e-f ). We also obtained diWe evaluated the ability of ,,(KLAKLAK),to disrupt mitochondrrect evidence for internalization from experiments based on cell ial membranes preferentially rather than eukaryotic plasma fractionation and mass spectrometry. CNGRC-GCG-,(KI.AKmembranes by mitochondrial swelling assays, in a mitochon-LAK),, but not CARAC-GG-t,(KLAKLAK) 2 , was indeed internaldria-dependent cell-free system of apoptosis, and by cytotoxic-ized and could be detected in mitochondrial as well as cytosolic ity assays"'. There was morphological evidence of damage to fractions (data not shown). mitochondrial membranes by electron microscopy. The peptide Next, we evaluated the efficacy and specificity of CNGRC-,(KLAKI.AK)2 induced considerable mitochondrial swelling at a GG-,(KLAKI.AK) 2 in a tissue culture model of angiogenesis2". concentration of 10 pM (Fig. 2a) . Mild swelling was evident During angiogenesis, capillary endothelial cells proliferate and even at 3 pM (data not shown), I% the concentration required migrate 2. Cord formation is a type of migration that can be to kill eukaryotic cells (approximately 300 pM), as determined studied in vitro by a change in endothelial cell morphology by the lethal concentration required to kill 50% of a cell mono-from the usual 'cobblestones' to chains or cords of cells 2 7. We layer (l,C,,; Table 1 ). These results demonstrate that )(KLAKtested the effect of CNGRC-GG-,,(KLAKLAK)2 on normal LAK), preferentially disrupts mitochondrial membranes rather human dermal microvessel endothelial cells (DMECs) in the than eukaryotic plasma membranes. Moreover, the peptide actiangiogenic conditions of proliferation and cord formation and vated mitochondria-dependent cell-free apoptosis in a system in the angiostatic condition of a monolayer maintained at composed of mitochondria suspended in cytosolic extract"', as 100% confluency. measured by characteristic caspase-3-processing from an inac-
The treatment of DMECs with 60 IEM CNGRC-GG-1,(KLAKtive zymogen to active protease"• (Fig. 2b) . A non-cx-helix-LAK) 2 led to a decrease in the percent viability over time comforming peptide, DLISI.ARLATARLAI (negative control), did not pared with that of untreated controls, in the conditions of induce mitochondrial swelling (Fig. 2a) , was inactive in the cellproliferation (Fig. 4a ) or cord formation (Fig. 4b) . In contrast, free system (Fig. 2b) and was not lethal to eukaryotic cells"'. We treatment with the untargeted peptide J(KI.AKLAK) 2 as a negaalso analyzed morphologic alterations in isolated mitochondria tive control led to a negligible loss in viability. Furthermore, the L1C,,, for proliferating or migrating DMECs treated with caspase 3 activity"'. We also tested a caspase inhibitor for its ef-CNGRC-GG-,(KI.AKI.AKI. peptide is pro-apoptotic. Although fect on cell death induced by CNGRC-GG-,(KI.AKI.AK)2. We the relatively early mitochondrial swelling is consistent with used Kaposi sarcoma cells, as these cells bind CNGRC. The inthe putative mechanism of action, that is, a direct activation of hibitor zVA).fmk, at a concentration (25 pM) that inhibits casthe apoptotic machinery, we cannot rule out the possibility pases but not non-caspase proteases, inhibited the cell death that the peptides actually kill by inducing some irreversible induced by CNGRC-GG-,(KI.AKIAK), (data not shown). This damage to cells which then activates the apoptotic program. result is compatible with the earlier demonstration that the In addition to the fluorescence studies shown above, we studp ied cultured cells by electron microscopy to confirm that *<• CNGRC-GG-,,(KI.AKI.AK)2 induces abnormal mitochondrial morphology in intact cells ( xenografts with CNGRC-GG-,(KIAKIAK), and (RGD-
.Given our results in culture, we proceeded to test both targeted pro-apoptotic peptides io vivo, using (0), as shown by a metastatic burden (Fig. 7) . lxperimental parameters inKaplan-Meier survival plot (n = 13 animals/group). P< 0.05, log-rank test.
cluded tumor volumes before and after treatment ( 
A R T I C L E S
The peptides were intact up to 1 hour in these conditions. In Morphological quantification of cellular apoptosis. Percent viability and the second set of experiments, mice were injected intra-LC,, (Table 1) were determined by apoptotic morphology" m . For the pervenously with the two targeted peptides and blood samples cent viability assay, DMECs were incubated with 60 pM active peptide or were analyzed; the peptides were present at 10 minutes after control peptide. Cell culture medium was aspirated at various times from administration (data not shown). We chose these short circula-adherent cells, and the cells were gently washed once with PBS at 37 'C.
Then, a 20-fold dilution of the dye mixture (100 lag/ml acridine orange tion times to coincide with the experimental conditions estab-and 100 pg/mI ethidium bromide) in PBS was gently pipetted on the cells, lished for 'homing' of targeted peptides in vivo".
which were viewed on an inverted microscope (Nikon TE 300). The cell Targeted pro-apoptotic peptides represent a potential new death seen was apoptotic cell death and was confirmed by a caspase acticlass of anti-cancer agents; their activity may be optimized for vation assay. Not all cells progressed through the stages of apoptosis at the maximum therapeutic effect by adjusting properties such as same time. At the initial stages, a fraction of the cells were undergoing residue placement, domain length, peptide hydrophobicity and early apoptosis. At later stages, this initial fraction had progressed to late hydrophobic moment 2 ". Beyond this, future targeted pro-apopapoptosis and even to the necrotic-like stage associated with very late totic peptides mlight he designed to disrupt membranes using a apoptosis (for example, loss of membrane integrity in apoptotic bodies). However, these cells were joined by a new fraction undergoing early apopcompletely different type of pro-apoptotic domain such as tosis. Thus, cells with nuclei showing margination and condensation of the [3-strand/sheet-forming peptides ". Our results provide a glimpse chromatin and/or nuclear fragmentation (early/mid-apoptosis; acridine orat a new cancer therapy combining two levels of specificity:
ange-positive) or with compromised plasma membranes (late apoptosis; 'homing' to targeted cells and selective apoptosis of such cells ethidium bromide-positive) were considered not viable. At least 500 cells after entry.
per time point were assessed in each experiment. Percent viability was calculated relative to untreated controls. LC,, for monolayer, proliferation Methods (60% confluency), and cord formation were assessed at 72 h. Reagents. Human recombinant vascular endothelial growth factor (VEGF; PharMingen, San Diego, California), antibody against caspase-3 (Santa Mitochondrial morphology. DMECs after 24 and 72 h of treatment with Cruz Biotechnology, Santa Cruz, California), streptavidin FITC (Sigma) and peptide were incubated for 30 min at 37 'C with a mitochondrial stain N-acetyl-Asp-Glu-Val-Asp-pNA (DEVD-pNA; BioMol, Plymouth Meeting, (100 nM MitoTracker RedT M CM-H 2 XRos; the nonfluorescent, reduced Pennsylvania) were obtained commercially. Peptides were synthesized to form of the compound) and a nuclear stain (500 nm DAPI; Molecular our specifications at greater than 90% purity by HPLC (DLSLARLATARLAI, Probes, Eugene, Oregon). Mitochondria were then visualized under fluoCoast (San Diego, California); all other peptides, AnaSpec (San Jose, rescence microscopy (1 00x objective) under an inverted microscope using California).
a triple wavelength filter set (Nikon). The computer-generated model was made with Insight I (Molecular Simulations, San Diego, California) running on an 0, work station (Silicon Electron microscopy. Rat liver mitochondria were prepared as described". Graphics, Mountain View, California)
The mitochondria were incubated either with a control peptide (DLSLAR-LATARLAI) or with 3 pM D(KLAKLAK),. The effects of the treatment were asCell culture. Dermal microvessel endothelial cells (DMECs) were grown sessed at different times (Fig. 2c) . Kaposi sarcoma cells were collected from in CADMEC Growth MediaTM (media and cells from Cell Applications, San 24-well Biocoat Cell culture inserts for electron microscopy (Becton Diego, California). DMECs were then cultured in three experimental conDickinson, Franklin Lakes, New Jersey). Cell monolayers at 80% confluency ditions: proliferation (30% confluency in a growth media supplemented were exposed to either 100 pM CARAC-GG-,(KLAKLAK), (control) or with 500 ng/ml VEGF); no proliferation (100% confluency in media for-CNGRC-GG-8 (KLAKLAK), (targeted) (Fig. 5) . All specimens were fixed with mulated to maintain a monolayer); and cord formation (60% confluency 3% glutaraldehyde in 0.1 M potassium phosphate buffer, pH 7.4 for 30 to (required for induction) in media formulated to induce cord formation). 45 min at the room temperature, followed by postfixation with aqueous KS1 767 and MDA-MB-435 cells were cultured as described'"" 2 8 . 1% osmium tetroxide and 2% uranyl acetate. After dehydration using a graded series of ethanol rinses, tissues were embedded in resin. Ultrathin Internalization assay. KS1 767 cells grown on coverslips were treated with sections after additional counterstainings were viewed and photographed 100 pM biotin-labeled CNGRC or biotin-labeled CARAC (negative control) on an electron microscope (Hitachi H-600). for 24 h. Streptavidin FITC was added to the coverslips, and cells were then viewed on an inverted microscope (Nikon TE 300) using a FITC filter. Human tumor xenografts. MDA-MB-435-derived tumor xenografts were established in female nude mice 2 months old (Jackson Labs, Bar Harbor, Mitochondrial swelling assays. Rat liver mitochondria were prepared as Maine) as described". The mice were anesthetized with Avertin as dedescribed"'. The concentrations used were 10 pM D(KLAKLAK)2, 10 pM DLscribed". The peptides were administered at a dose of 250 ag/week per SLARLATARLAI (negative control), or 200 pM Ca'* (positive control). The mouse, given slowly through the tail vein in a volume of 200 p1.. Three-dipeptides were added to mitochondria in a cuvette, and swelling was quanmensional measurements of tumors were made by caliper on anesthetized tified by measuring the optical absorbance at 540 nm.
mice, and were used to calculate tumor volume'". Then, tumors and lungs were surgically removed and the wet weights recorded. Animal experiCell-free apoptosis assays. Cell-free systems were reconstituted as dementation was reviewed and approved by the Institute's Animal Research scribed'". For the mitochondria-dependent reactions, rat liver mitochondria Committee. were suspended in normal (non-apoptotic) cytosolic extracts of DMECs. The peptides were added at a concentration of 100 pM. After incubation Acknowledgments for 2 h at 30 'C or 37 'C, mitochondria were removed by centrifugation, We thank W.K. Cavenee and G. Salvesen for comments and critical reading of and the supernatant was analyzed by SDS-PAGE and immunoblotting the manuscript. This work was supported by grants CA74238, CA28896 (to (12% gels, BioRad, Richmond, California). Proteins were transferred to ER) NS33376 and Cancer Center support grant CA30199 (to R.P., D.B. and PVDF membranes (BioRad, Richmond, California) and incubated with anti-E.R.) from the National Cancer Institute (USA), and DAMD 17-98-1-8581 (to body against caspase-3, followed by ECL detection (Amersham).
D.B. and R.P.) from the DOD-PCRP. H.M.E. is the recipient of a NS100SO
Caspase activity of cell lysates. The caspase activity of DMEC lysates was NRSA senior fellowship grant. W.A. is the recipient of a CaP CURE award. measured as described'". Aliquots of cell lysates (1 pl lysate; 8-15 mg/ml) were added to 100 p M DEVD-pNA (100 p1; 100 mM HEPES, 10% sucrose, 0.1% CHAPS and 1 mM DTT, pH 7.0). Hydrolysis of DEVD-pNA was moni- tored by spectrophotometry (400 nm) at 25 'C. Abstract We have previously described a novel cancer chethe length of these peptides. we designed a Computational motherapeutic approach based on the induction of apoptosis approach to detect short, linear and specific pro-apoptotic in targeted cells by homing pro-apoptotic peptides. In order peptides. to improve this approach we developed a computational method Apoptosis in mammals and other eukaryotic organisms is a (approach for detecting potential apoptotic peptides, APAP) characteristic process of cell death, which can, among its other to detect short PAPs, based on the prediction of the helical effects, limit the spread of viruses and other intracellular orcontent of peptides, the hydrophobic moment, and the isoganisms [4] . For example, the difference in viral titer during electric point. PAPs are toxic against bacteria and mitobaculoviral infection with and without apoptosis inhibition is chondria, but not against mammalian cells when applied 200-15000-fold [4] . Thus apoptosis is a mechanism of defense extracellularly. Among other peptides, substance P was identiagainst pathogenic infections. tied as a PAP and subsequently demonstrated to be a proApoptosis proceeds by the activation of a group of cysteine apoptotic peptide experimentally. APAP thus provides a method potosis ce es by the of ahgroup of ctin to detect and ultimately improve pro-apoptotic peptides for proteases called caspases [5] . One of these. caspase-9, is actchemotherapy. family. such as Bax and Bid. although the mechanism by which this is achieved is incompletely understood [7] . None-1. Introduction theless, the similarities between bacterial and mitochondrial membranes (and membrane potentials) suggested the possibilWe have previously described the finding that an antibacteity that there may be similarities between the effect of the rial pcptidc. when targeted intracellularly to the angiogenic antibacterial/pro-apoptotic peptides and pro-apoptotic Bcl-2 vasculaturc (ie. to the endothelial cells) supplying tumors, family members. can induce apoptosis by swelling their mitochondria [I], leadAntibacterial peptides in mtulticelhllar organisms are ing to the loss of tumor blood supply and consequent tumor thought to serve as a defense against microbial pathogens. regression. We named these chemotherapeutic peptides homOriginally found in invertebrates, antibacterial peptides have ing pro-apoptotic peptides. We designed the pro-apoptotic now been described in humans and many other organisms [2] . part of the peptides to induce endothelial cell apoptosis Among these peptides. the most well characterized are the through mitochondrial swelling. The peptides are positively short linear peptides (less than 40 amino acids in length) charged and the mitochondria, like bacteria, have negatively that do not contain cysteine residues. A characteristic shared charged membranes, thus the peptides are attracted to and by virtually all of these peptides is the presence of an amphidisrupt the mitochondrial membrane [2.3] . The initial results pathic cx-helical structure, which stabilizes in environments of were obtained with a 21-residue peptide, of which the carhydrophobic nature [8] (although this helical structure has boxy-terminal 14 amino acids represented the pro-apoptotic been shown not to be necessary for membrane lysis produced peptide, with the amino-terminal seven amino acids comprisby a truncated form of pardaxin, an antibacterial peptide ing the targeting peptide and a glycinylglycine bridge. The from the sole Pardachirus marmoratus [9] ). Another charactertherapeutic index (TI) of the initial pro-apoptotic peptides is istic shared by some of these peptides is selectivity, in that approxiirately 10. In order to increase the TI and minimize membranes from bacteria are targeted by these peptides more efficiently than mammalian plasma membranes. This selectivity is based on the complementary charge between *Corresponding author. Fax: (1) (Tables 2A and  2B ). The peptide sequteices of this subset are shioswn in Table 1 .
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The TI of a peptide is here defined as the ratio between the itiliib-I)1-5Ix ELheri(Ihi coi cells iscre gro\ssi oxernighlt as a pri-ielocutor\ concentration obsersed v5ith Iianmnialian cells and the inilibitory luni for the bacterial culture uised in this assa\. When the cells 5\crc at concentration observed with bacterial cells (Tables 2A and 2B ). The the end of their log phase (optical ldensity at 600 nim of I.t I1.1)1 I ill higher the \sattle of this ratio is, tihe miore specilic ttie peptide is for Was used to iotcuttfl Ic 5 111I. Such dilution produced iinitialt cocctraprokarxotic (negatisel\ charged) iieimibranes.
tions of bacteria capable o' forming 10 I0' colonies per rut in I1
PAPs xere searched for in the SwissProt database, release 38 [12] .
plates at 37C( thiat is I0t 10" cotlon formtring Units. cell-free system. This system was developed previously in our grouip to simulate neuronal apoptosis (see Section 2 3. Results and [14] ). We observed that SP induces the swelling of mitochondria at 50 pM in our system (data not shown). At such The antibacterial peptides analyzed and biophysical properconcentration, SP was capable of relcasing cytochrome c ties previously determined are presented in Tables I and 2A, from mitochondria and activating caspase-3 (Fig. I) . In conrespectively.
trast, a peptide chosen as negative control (see Section 2) In order to reproduce these biophysical properties. we calwhich did not present the properties of PAPs (data not culated three scores from the sequences of these pcptides.
shown) did not display any observable effect on mnitochondria Table 2A showxs a subset of selected antibacterial peptide se- (Fig. 1) . quences (see Section 2) and the corresponding experimental values lor helix formation in water and in hydrophobic envi-
TI of'SP ronments, antibacterial activity and cytotoxic activities against
The toxicity of SP against bacteria was tested and cornmamnmalian cells. Table 2B shows the corresponding calcupared to the effect of SP on fibroblasts wx hen applied extralated values for 11, Ill, A and the 11. We observed that the cellularly. SP was able to reduce the growth of L. colt cells antibacterial peptides presented in Table I are more potent with an ICOcu of 10 M (Fig. 2B) . By comparison, the negative against G(-) (M IC= 17.3 ig/mIl on average) bacteria than to control pcptide did not have any toxicity against bacteria. In Q(+) (MIC=44.3 ftg/ml), and we used the G(-I values as a contrast. Fig. 2A shows that SP did not affect the growth of reference lor the TI.
fibroblasts when applied extracelltLlarly even at a concentraPeptide sequences wx ith values ranging from 0J.4 < 1f <0.6, tion of I raM. These results indicate that SP has a TI > 100.
A < 1It). and 10.8 < IP < 11.7. were found to have the highest Additionally, a peptide from the protein APP (the last 31 TI (highest specificity for bacteria) (Fable 2B). These paramamino acids in APP, referred as C31) known to induce apoeters were therefore hypothesized to be the signature of the ptosis when expressed intracellularly [16] was tested for its PAPs. Searching for PAPs in the SwissProt database led LIs to toxicity against bacteria and mammalian cells. This peptide identilf 14 PAPs (Table 3) . Two of these peptides have predid not present the properties (IP, AL. .4 scores) of PAPs viously been characterized with respect to their toxicity (data not shown). C31 did not present any observable toxicity against bacteria and mammalian cells, and in both cases a against bacterial or mammalian cells when applied extracelgreater toxicity towards bacterial cells was observed (Table 3) . lularly ( Fig. 2A.B) .
[ 160-nm2a 7 I GF1KVKSFGKSWIGETMNs-NH2
The amino acids ill the peptide sequence are represented inl a one-letter code. Table I for the amino acid composition for each peptide described in this table. CD Observed in water or lipid: percent of e1-heli- thus PAPs would be expected not to be simply highly hydroIn order to optimize our homing pro-apoptotic approach to phobic peptides. We observed that in our group of peptides target and kill angiogenic endothelial cells supplying cancer ( Table 1) , all of the peptides but one were hydrophilic. concells, we have developed APAP. an approach to detect PAPs.
. de'l Rio et alIFEBS letcr., 404 (2001 213 219
stituting an appropriate group of peptides from which to se-APAP was originally developed to overcome the problems of lect PAPs. It has been shown previously that antibacterial toxicity and synthesis associated with our chemotherapeutic peptides with lower hydrophobicity display higher specificity approach [1] . Positively charged PAPs, which are non-toxic towards Gram-negative bacteria [20] . In agreement with this outside the cell, are targeted to tumor vasculature by a fusion notion, all the peptides analyzed in otir study presented higher with a peptide that recognizes a receptor on the cell surface specificity towards G(-) bacteria as expressed by the TI val- [17, 18] and consequently internalized where they disrupt the ties (Tables 2A and 2B) . negatively charged mitochondria, thereby exerting their proAlternatively, the propensity to form soluble structures in apoptotic effect.
water (expressed by the propensity to form secondary strucWe calculated the amphipathicity, IP and AGADIR scores for a subset of 30 different antibacterial peptides. Peptide: see Table I for the amino acid composition tor each peptide described in this tures in water, AGADIR score) was used in our approach. in our analysis because they were deposited in the SwissProt Since hydrophobicity and the propensity to form soluble database in their mature form. In this form, they were longer structures in water are inversely related, it is expected that than the cut-off value used to define the peptide database hydrophobic sequences will display a low AGADIR score.
analyzed in this study (see Section 2 for a description of the The inverse is not necessarily true, though: that is. peptide peptide database used in this study). Alternatively. two cecrosequences with low AGADIR scores are not necessarily hypins (cec4_bomino, cecb.antpe) and two other natural antidrophobic. Interestingly, PAPs tend to be hydrophilic with bacterial peptides (crblvescr, dms3_physa) were found in our low AGADIR scores (Tables 2B and 3) .
search. In agreement with our predictions, these antibacterial The peptides used to define the parameters of the PAPs peptides have been reported to have TIs similar to PAPs (Ta- (Table I) are mostly synthetic peptides, with the exception ble 3). As further evidence of the validity of our approach, we of three natural peptides (magainin, cecropin A and melittin).
tested two peptides, C31 and a control, that did not match the None of these three natural peptides in Table I were detected IP. M and A scores of PAPs (Fig. 2) . The C31 peptide has -------.----------------------............ more effective antibacterial peptides with higher TI values.
In conclusion, we have described a computational approach. APAP. to identilt' PAPs. l'hese peptides display sebeen shown It) induce apoptosis by all unknown mechanism lectivity towards bacteria and mitochondria, whith little toxic
[16], so xxe considered it an interesting target for our study effect on eukaryotic cells wvhen applied extracellularly, thus since we might provide some hints on the mechanism of acproviding the basis lor a nle\ generation of drugs that can tion of ('31 in addition to testing our approach. We found be present in the body wxiihout toxic effect unless they are that none of these peptides is toxic to bacterial or manmmalian taken in by targeted cells as We have shown prexiousls [1], cells when applied extracellularly thus confirming our predicFrom ia public database, the approach detected mostly antitions. Based on these results we propose that C31 may induce bacterial peptides and neuropeptides suggesting that these apoptosis by a different mechanism than PAPs.
neuropeptides may be the first reported wxith antibacterial acIn total, 14 sequences were identified as PAPs in the Swisstivity. It agreement wxith this idea. we reported that SP is it Prot database (see Section 2). These 14 peptides can be placed PAP with a TI > 100. We speculate that these activities have into Iour diflerent groups based on their known function: i.e. been present in SP during the course of Cvolutiorn of the antibacterial peptides. neuropeptides, mast cell degranulating tachykinins. which Weould support the possibility of a biologpeptides and protein protein interacting peptides. Two out of ical signiticance for these findings. APAP provides a method these four groups, antibacterial peptides and neuropeptides, to detect and ultimately improxe pro-apoptotic peptides for represent more than 80W' of the total ( Organ specific drug targeting was explored in mice as a possible CA). The pumps were loaded with peptides following the alternative to surgery to treat prostate diseases. Peptides that manufacturer's instructions. specifically recognize the vasculature in the prostate were identified from phage-displayed peptide libraries by selecting for phage Mice. CD-1 male mice (The Jackson Laboratories) were used for capable of homing into the prostate after an i.v. injection. One of phage screening at an age of 2-4 months. Transgenic adenothe phage selected in this manner homed to the prostate 10-15 carcinoma of the mouse prostate (TRAMP) mice, kindly protimes more than to other organs. Unselected phage did not show vided by Norman Greenberg, Baylor College of Medicine, this preference. The phage bound also to vasculature in the human Houston) were bred at our Animal Facility. prostate. The peptide displayed by the prostate-homing phage, SMSIARL (single letter code), was synthesized and shown to inhibit Phage Libraries and Library Screening. The phage libraries were the homing of the phage when co-injected into mice with the prepared in the fUSE5 vector as described (6, 7). The primary phage. Systemic treatment of mice with a chimeric peptide conlibrary contains about 5 X 101 individual recombinant phage. sisting of the SMSIARL homing peptide, linked to a proapoptotic For the library screening, CD-I mice were anesthetized with peptide that disrupts mitochondrial membranes, caused tissue Avertin (0.015 ml/g) and injected intravenously (tail vein) with destruction in the prostate, but not in other organs. The chimeric phage libraries containing 109 transducing units diluted in 200 A 1 peptide delayed the development of the cancers in prostate cancerof DMEM. The phage was rescued from tissues by bacterial prone transgenic mice (TRAMP mice). These results suggest that it infection (2), and about 300 individual colonies were grown may be possible to develop an alternative to surgical prostate separately. The bacterial cultures were then pooled and the resection and that such a treatment may also reduce future cancer amplified phage were injected into mice as described above. To risk.
test individual phage for homing, 109 colony-forming units (cfu) (fUSE5) or 1010 plaque-forming units (pfu) (T7), diluted in 200 a eel of PBS, were injected. The SMSIARL insert and its scrambled iseases affecting the prostate have gained majorsignificance variant were cloned to the T7 phage (T7select4l5-1 vector; * clinically and economically, primarily because of the inNovagen), and the resulting phage was tested as described (8) . creasing average age of the male population in the industrialized countries. Benign prostate hyperplasia affects to some degree Results most elderly men. Even more serious, the prostate is a frequent
[n vivo screening of a fUSE5 phage heptapeptide library for site of cancer. Some autopsy studies find that most men older prostate-homing peptides (6) yielded two phage that accumuthan 70 have occult or overt cancer in the prostate (1). The lated selectively in the prostate. One of these phage, displaying surgical therapies of prostate hypertrophy and prostate cancer the peptide SMSIARL (single letter code), homed to the are associated with serious side effects, such as incontinence and prostate 15 times more than nonrecombinant control phage (Fig.  impotence.  1a) . The other prostate-selected phage (VSFLEYR) gave a We have sought to develop a strategy that would provide a less prostate-homing ratio of -10. The homing of the SMSIARL traumatic treatment for prostate disease than is currently availphage to prostate tissue was inhibited when synthetic SMSIARL able. Our strategy is based on identification of peptides that peptide was injected together with the phage, but not when an home to specific sites in the vasculature by in vivo screening of unrelated peptide was injected (Fig. ta) . The SMSIARL phage intravenously injected phage libraries. These studies have revealed a surprising degree of specialization in the endothelia of here the identification of peptides that home to the vasculature SPresent address: Ordis Biomed, Institut fur Pathologie. LKH-Universitatsklinikum Graz.
of the prostate and the use of one of these homing peptides to Auenbruggerplatz 25, 8010 Graz, Austria. deliver a proapoptotic peptide to the prostate. The SMSIARL peprtide directs specific homing of T7 phage to the prostate. The SMSIARL sequence was cloned to the coat protein of the T7. A 1:10 mixture of SMSIARL and nonrecombinant control T7 phage 11010 plaque-forming units (pfu)] was injected and allowed to circulate for7 rain. Phage was extracted from prostate and brain with buffer (PBS), or a detergent solution (0.5% Nonidet P-40 in PBS) and plated, and 32 colonies were randomly chosen for PCR. The PCR products of SMSIARL and control phage DNA were distinguished on the basis of a size difference in a 4% agarose gel. (Control tissue was brain.)
homed also to the rat prostate tissue (not shown). The SMSIARL phage and nonrecombinant phage; the ratio of the SMVSIARL peptide when cloned into the T7 phage (6) showed two types of phage in the prostate was determined by PCR. The a similar homing specificity for the prostate. SMSIARL phage homed to the prostate 10-15 times more than Phage displaying a scrambled variant of this peptide (LAMthe nonrecombinant phage. The recovery of the SMSIARL SRIS) showed no homing to the prostate. The T7 SMSIARL phage was more than 5-fold higher when the tissue was extracted phage was not enriched in the brain (Fig.  pb) , salivary gland, with detergent rather than buffer alone. The brain as a control kidney, testis, thymus, pancreas, skeletal muscle, or lung (not organ showed no enrichment with or without detergent (Fig. lb) . shown)b We also confirmed the homing specificity by co-injecting
The greater phage recovery after lysis of the tissue with deter- Fig. 2 . Immunoihistochemical staining of phage within prostate endothelial cells after i.v. injection into mice. SMSIARL-phage preparation was injected intravenously into mice. After 7 fin circulation, animals were perfused with PBS, the prostate (a-c), brain (d-f), and various control organs were removed, processed for frozen sectioning, and stained with a polyclonal antibody against T7 phage (FITCn a and d) and CD31 (rhodamine; b and ey. Merge with nuclear counterstain with DAPI (c and f). Control organs (kidney, spleen, lung; not shown) were negative for the phage, except for liver and spleen, where the reticulsendothelial tissue traps phage nonspecifically (4). (Magnification: s400.) gent suggests that the SMSIAR L phage may have been taken up homes to tumor vasculature, D(KLAKLAK) 2 yields a chimeric into cells, compound that is selectively cytotoxic to angiogenic endothelial Antibody staining of the phage in tissue sections from mice cells and has antitumor activity in vivo (10) . We used the same injected intravenously with the T7 SMSIARL phage revealed strategy to prepare a proapoptotic chimera that targets the staining in the prostate 7 min after an i.v. injection (Fig. 2) . The vasculature of the normal prostate, and studied its ability to phage staining colocalized with staining for the blood vessel cause selective tissue destruction in the prostate. marker CD3t, indicating homing to blood vessels in the prostate.
Mice were injected with 250 A.g of the targeted SMSIARLNo specific staining was seen in control organs, or in prostate or GG-D(KLAKLAK)2 chimeric compound and the prostates were control organs of mice injected with a nonrecombinant control collected after 1, 4, 8, 12, 16, 24, and 48 h, and after 7 days. phage. The phage staining appeared to be intracellular, supControl groups received D(KLAKLAK) 2 coupled to a nonporting the detergent extraction results shown in Fig. lb . Overlay homing scrambled peptide (LAMSRIS), SMSIARL and of tissue sections from human prostate with the SMSIARL D(KLAKLAK) 2 as an uncoupled mixture, or buffer alone. A phage indicated that this phage also binds to the endothelium of total of 62 mice treated with SMSIARL-GG-D(KLAKLAK) 2 human prostate blood vessels the same way it binds to the mouse were evaluated. In prostates collected 16 h or later after the huma prstae blod essls he sme ay t bnds o te muse injection, histology revealed an unevenly distributed destruction prostate vessels (Fig. 3) . Significantly, vessels in hypertrophic ofj theo prostat e aledu a n e vel y disthat des tructiea human prostate tissue bound the SMSIARL phage. No binding of the prostate glandular epithelial cells that in some areas h included epithelial shedding and destruction of entire glandular of this phage was detected in the blood vessels in several other structures (Fig. 4 a and b) . These changes were still present 7 days human tissues. Similar localization results were obtained with after the treatment and no mitotic figures were observed, the free SMSIARL peptide coupled to fluorescein (data not suggesting sustained damage and poor regeneration (not shown).
shown). Electron microscopy showed extensive destruction of We next studied the ability of the SMSIAR L peptide to deliver intracellular organelles in the SMSIAR L-GG-D(KLAKLAK) 2 -a biologically active compound to the prostate. D(KLAKLAK) 2 treated, but not control-treated, mice (Fig. 4 c and d) . Tissue is an amphipathic D-amino acid peptide that binds selectively to damage was also evident from an increase in TUNEL-positive bacterial, but not eukaryotic cell membranes (9) . It has antibacvascular and glandular cell nuclei in the prostates of mice treated terial activity, but is relatively nontoxic to eukaryotic cells. We with SMSIARL-GG-D(KLAKLAK)2 (not shown). The proshave previously shown that D(KLAKLAK) 2 , if delivered into tates of control animals displayed only rare degenerating epimammalian cells, disrupts mitochondria (mitochondrial memthelial cells and all other organs examined (brain, heart, liver branes resemble those of bacteria), initiating apoptosis (10) .
kidney, lung, urothelium) were histologically normal during or Conjugated through a G-G linker to a homing peptide that after treatment with each of the compounds (Fig. 4 e--h ). c and d, X6 ,000.) Light microscopy shows no damage to bladder (e; x200), heart(tf x400), kidney (g; Discussion x400), or liver (h; x400).
We show here that peptides selected from phage libraries for homing to the prostate vasculature reveal tissue-specific features To effect sustained levels of the compounds used in the in the blood vessels of the prostate. We also show that a peptide treatments, we used an implanted peristaltic pump for controlled capable of homing to the blood vessels in the prostate can target release. Each pump was loaded with either SMSIARLa proapoptotic peptide to the prostate, and that systemic treat-D(KLAKLAK) 2 or an uncoupled mixture of SMSIARL and ment with this targeted compound can cause destruction of D(KLAKLAK) 2 . The animals were killed after 1 week, and their prostate tissue and delay the development of prostate cancer in organs processed for histology. In another control experiment, mice. Our results show that, like the vasculature of many other we also implanted s.c. testosterone pellets to eliminate any tissues analyzed in previous work (2-4), the vasculature of the variation in the sensitivity of prostate tissue caused by possible prostate is biochemically distinct. The accumulation of the fluctuations in endogenous androgen levels (11). Seven days SMSIARL phage and fluorescein-labeled SMSIARL peptide in later, controlled release pumps loaded with the peptides the prostate blood vessels after an i.v. injection indicates that this were implanted on the peritoneal area opposite the pellets.
peptide binds selectively to the blood vessels in the prostate. The selective destruction of prostate tissue caused by targeting of a alternative treatment for prostate hypertrophy. Furthermore, proapoptotic peptide to the prostate with the SMSIARL homing the proapoptotic peptide treatment postponed the development peptide supports this conclusion, of prostate cancer in TRAMP mice. We attribute the effect in The molecular nature of the vascular specialization is incomthe TRAMP mice to a reduction in the number of target cells pletely understood. We have identified the receptor for a peptide available for malignant transformation, because the SMSIARL that homes to lung vasculature as membrane dipeptidase (13) .
peptide does not home to the vessels in the TRAMP tumors Others have shown that a modified von Willebrand factor (W.H. and E.R., unpublished result). The lifespan extension in promoter is activated in endothelial cells in a tissue-specific our treated TRAMP mice was 6-8 weeks, close to 20% of the manner under the influence of the surrounding parenchymal lifespan, even though the treatment works against a tremendous tissue (14), providing one possible regulatory mechanism for the oncogenic pressure in these transgenic mice (12, 15) . In human expression of tissue-specific endothelial markers. Perhaps prosterms, this would mean postponement of prostate cancer develtate tissue induces receptors for SMSIARL in the resident opment for several years. A medical treatment that reduces the endothelium. Although the molecule the SMSIARL peptide size of the prostate and at the same time delays the development binds to in the prostate vasculature remains to be identified, our of prostate cancer could be an extremely useful procedure. results suggest some practical applications.
The destruction of prostate tissue by the SMSIARL-targeted We thank Dr. Norman Greenberg for providing TRAMP mice and Eva proapoptotic peptide is likely to be secondary to loss of blood Engvall for comments on the manuscript. This work was supported by vessels, the main target of the homing peptide. However, we Grants DAMDI7-99-1-8164 (to W.A.), DAMDI7-98-8581 (to D.E.B.), cannot exclude a direct effect on prostate epithelial cells. The and DAMD17-98-1-8562 (to E.R.) from the Department of Defense, tissue damage was specific for the prostate, suggesting that it may research awards from CaP CURE (to W.A. and E.R.), and Grants be possible to develop a "medical prostatectomy" procedure CA74238 and CA82713 (to E.R.) and Cancer Center Support Grant based on this principle. Such a procedure could provide an CA30199 from the National Cancer Institute.
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Hydrophobic leucine and alanine residues are shown in red, and positively trates the fact that the altering the structure of SGP can diminish its anesthetized with Avertin as described (29). SGP was administered cell death inducing ability. The dash marks (-) indicate no data obtained. directly into the center of the tumor mass at a concentration of 100 AM or 1 mM given slowly in 5 M 1 increments, for a total volume of 40 p1. LC6, at 30 rini M e a s u r e m e n t s o f t u m o r s w e r e t a k e n b y c a l i p e r u n d e r a n e s t h e s i a a n d C e l l L i n e -... ... -. ---------------------------- Cytotoxicity Assays-Cell viability was determined by morphology (29, 30). KS1767 cells were incubated with SGP at 1 mm in the presence or absence of matrigel or polymeric fibronectin (sFN). The fibronectin positivity. Such a rapid response suggests that the plasma polymer was produced as described (31) . Briefly, cell culture medium was aspirated from adherent cells. Cells were then coated with matrigel (gently pipetted on each well to completely coat the entire cell layer), or SGP to between 5 and 10 AM led to induction of necrosis (scored the fibronectin polymer, and incubated at 37 'C for 10 min. SGP was morphologically), resulting in almost 100% loss of KS1767 cell added and the cells were viewed on an inverted microscope (Nikon TE viability over 60 min (Fig. 2B) . SGP levels below 5 ALM led to the 300). KS1767 cells were also exposed to doxorubicin (20 Ag/well) or SGP induction of apoptosis over a 24-hour period (Fig. 2C) , which in the presence or absense of matrigel for 24 h. Cell viability (%) was was confirmed by a caspase-3 activation assay. KS1767 cells evaluated after no treatment (medium or matrigel alone), incubation with SGP or doxorubicin. Cell death was evaluated morphologically (29, 30), and cell viability was compared relative to untreated controls (no peptide (Fig. 2D) . However, the classic morphological signs of matrigel) or absence of SGP.
apoptosis, such as nuclear condensation (Fig. 2E , short arrow) and plasma membrane blebbing (Fig. 2E, long (Table I) . These lines included the Kaposi's leukemic cell lines) and non-neoplastic cells (including endosarcoma-derived cell line KS1767, the breast carcinoma-dethelial cells and fibroblasts isolated from multiple organs and rived cell line MDA-MD-435, and the microvessel endothelial cells of glial origin, Table I ). As negative controls, we used cell line dermal microvessel endothelial cells (27) (28) (29) . Treataltered forms of SGP (SGP-L and SGP-E). In SGP-L, the cenment of KS1767 cells with >10 AM SGP led to rapid nontral all alanine helix was replaced by an all leucine helix. In necrotic, non-apoptotic cell death, characterized by 100% loss of SGP-E, lysines have been replaced by glutamic acids, and we viability within 60 s ( Fig. 2A) , as determined by Trypan Blue had previously determined that the ability of such analogs to SGP-E were substantially less toxic to mammalian cultured cells (Table I ). The LC 0 o was increased by at least 10-fold in all • 2 cell types tested with SGP-L and SGP-E when these inactive E
versions of the protein were tested. These observations clearly •
show that the integrity of the SGP helices is required for SGP E membrane disrupting activity. Taken together, these data -0 demonstrate that SGP is a potent membrane-disrupting agent, . 1000 C but also that it is not cell-selective and it will affect tumor- (Fig. 3A) . Starting tumor closed circles). Differences in tumor volumes at 8 weeks are shown (t volumes ranged from about 100 mm 3 to large sizes of about 600 test, p < 0.05). A total of 10 mice received SGP. B, representative pictures of tumors after 4 weekly treatments with SGP at 40 MI/week, mm 3 . Tumor-bearing mice were given four weekly treatments n = 5 for each experimental group. The volume of the PBS-treated of PBS, or 100 AIM or 1 mM SGP (40 Jil/treatment given in 5 Al tumor is 400 mmin (left), whereas 100 JiM SGP (middle) and 1 mm SGP increments). After a 4-week period without treatment, the tu-(right) treated tumors have flattened and virtually disappeared. These mor volumes were measured at 8 weeks. The average tumor three tumors began at volumes of 100 mm'. C, lack of skin toxicity of SGP. Subcutaneous injection (40 ul) of 100 1M SGP (left injection sight, volume at the end of the experiment in the SGP-treated groups arrow) and of PBS (right injection site, arrow) demonstrates that SGP is was 5X less than the average volume seen in the PBS-treated relatively non-toxic to normal skin. Results represented in C were group (Fig. 3A) . There was no difference between the average reproduced in eight independent experiments. B %tumor volumes of the 2 SGP treatment groups. Mice treated with SGP remained tumor-free for up to 4 months after tumor implantation, before being euthanized for histological evaluation. These observations indicate that both primary tumor E growth (Fig. 4) and metastases were inhibited. Surgical examination of the tumor sites revealed no sign of tumor cells. Similar results were obtained when xenografts were produced by injection of prostate (Fig. 5A ) and lung carcinoma (Fig. 5 , B and C) cell lines. By successfully treating a large number of mice and testing the effects of SGP on several different tumor xenograft models (including carcinomas, sarcomas, and melanomas), we firmly established the therapeutic properties of SGP. Our data also show that that the anti-tumor effects of SGP are not limited to a specific tumor type. We also deterk mined whether SGP produced adverse side effects such as necrosis when injected under normal skin. Strikingly, in all PaBSmice tested, SGP did not produce any surface effect when r injected intradermally or sub-cutaneously (Fig. 3C ) when com-,o pared with mice that did not receive the active form of SGP.
o Histopathological analysis of SGP-treated MDA-MD-435 hu-E man breast carcinoma xenografts showed widespread cell V-_ death (Fig. 4 , upper right panel), as compared with PBS-treated P.-tumors (Fig. 4, upper left panel) . Many condensed nuclei were apparent (Fig. 4 , upper left panel, short arrows), and there was no effect on the extracellular matrix (Fig. 4B, long arrows) .
U)
Apoptosis was confirmed by a caspase-3 activation assay (data not shown). It is noteworthy that whereas 100 p•m SGP induced almost immediate cell death in vitro that was apparently neither apoptotic nor necrotic, 100 A•m SGP induced apoptosis in vivo. Work is underway to evaluate lower concentrations. SGPtreated human KS1767 Kaposi's sarcoma-derived xenografts Cytotoxic assay in vitro and effects of matrigel. A, KS1767 cells were exposed to doxorubicin or SGP in the presence or absence of matrigel for 24 h. Cell viability (%) was evaluated at 24 h after no treatment (medium or matrigel alone), or incubation with SGP or doxorubicin (20 pg/well), as indicated. In contrast to SGP, doxorubidin decreased cell viability (*, p < 0.01) in the presence of matrigel. Shown are S.E. obtained from triplicate wells. Results were reproduced in four independent experiments, B, KS1767 cells were exposed to SGP in the presence or absence of polymeric fibronectin. In contrast to cells exposed to ethanol, cells treated with 1 mm of SGP in the presence of polymeric fibronectin (sFN) remain unaffected (*, p < 0.01). Cell viability (%) was evaluated morphologically. Shown are S.E. obtained from triplicate wells. Results were reproduced in three independent experiments. assay (to mimic extracellular matrix). In the absence of matri-interfere with cell viability (Fig. 7A) , whereas ethanol induced gel, SGP led to severe disruption of cell membranes, resulting massive cell death. Fibronectin alone did not prevent SGP in almost 100% loss of viability over 10 min (Fig. 6B) . In activity and was used as a control. contrast, in the presence of matrigel, KS 1767 cells were unaf-
The observations in this model are consistent with the lack of fected by incubation with 1 mm SGP (Fig. 6D) . This loss of skin toxicity seen with SGP. We propose that the discrepancy membrane disrupting ability in the presence of a thin matrigel between in vitro and in vivo SGP effects (anti-tumor cell activlayer could account for the lack of SGP toxicity seen in vivo. ity versus selective anti-tumor activity) results from the potent Ethanol, as shown in Fig. 7A , or cytotoxic drugs such as doxo-membrane-disrupting activity of SGP, which is inactivated in rubicin (Fig. 7B ) damaged the cell layer under similar condi-the presence of extracellular matrix and connective tissue. tions, regardless of the presence of matrigel, which fails to provide protection from the other toxic agents because these DISCUSSION other agents more readily diffuse through the matrix. When SGP represents a novel class of anti-cancer proteins whose matrigel was replaced by polymeric fibronectin (sFN) (31), an-therapeutic effects can be optimized by amino acid substitution other form of matrix, SGP was also ineffective and did not and by altering helical domain length and hydrophobicity (32).
